Close Menu
    Facebook X (Twitter) Instagram
    BusinessNews.phBusinessNews.ph
    Subscribe
    • Top Stories
    • Business
    • Events / Conventions
    • National
    • Technology
    BusinessNews.phBusinessNews.ph
    Home » Olympus to Acquire Quest Photonic Devices B.V. to Bolster Surgical Endoscopy Capabilities
    Medical

    Olympus to Acquire Quest Photonic Devices B.V. to Bolster Surgical Endoscopy Capabilities

    By Marie JonesJanuary 28, 2021
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Olympus Corporation (Olympus – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) today announced that it has entered into an agreement to acquire Quest Photonic Devices B.V. (Quest – CEO: Richard Meester) for up to EUR50 million including milestone payments to strengthen its surgical endoscopy capabilities.

    Headquartered in the Netherlands, Quest offers advanced fluorescence imaging systems (FIS) for the medical field, enabling more surgical endoscopy capabilities, compared to conventional imaging technologies.

    Fluorescence imaging refers to special light imaging technologies that utilize the properties of fluorescent dyes directed to specific anatomical structures. By using targeted dyes, in combination with specific light wavelengths, tissues or lesions that are nearly invisible under normal white light become visible. Olympus’ existing laparoscopic imaging system, VISERA ELITE II, is already equipped with fluorescence imaging technology. VISERA ELITE II uses near-infrared light to identify blood vessels or lymph nodes under the surface tissues, aiming to assist surgeons in performing safer procedures with lower complication risks. The Quest technology acquired is intended to expand opportunities for Olympus in this field.

    Making the Invisible Visible

    Quest offers innovative technologies for multi-spectral imaging and imaging systems for medical applications, ranging from fluorescence imaging to photodynamic therapy. The acquisition strengthens Olympus’ position as a world leader in medical imaging solutions, and delivers innovative capabilities (including 3D and 4K imaging) to surgeons, to “make the invisible visible.”

    Quest’s lead product line is the Quest Spectrum Fluorescence Imaging System, which enables fluorescence-guided surgery for open and minimally invasive procedures. Kanichi Matsumoto, global head of Surgical Endoscopy at Olympus, said: “We are delighted to incorporate Quest’s advanced FIS capabilities into our comprehensive medical imaging portfolio. The combination of the Quest Spectrum product line’s leading FIS technologies with Olympus’ existing laparoscopic imaging system VISERA ELITE II will enable Olympus to offer surgeons a wide range of high quality fluorescence imaging solutions.”

    New Applications and Market Growth

    The global market for FIS devices is expected to grow at a compounding annual rate of more than 12%, from around US$310 million in 2018 to over US$827 million in 2027*. Increasing demand for minimally invasive procedures and reconstructive surgery is helping to drive FIS growth worldwide. Furthermore, application of the FIS technology is expected to expand over the coming years, as additional fluorescent dyes are paired with targeted antibodies. Among other applications, molecular imaging will allow healthcare professionals to visualize cancerous lesions in vivo and perform cancer surgery in unprecedented ways, potentially lowering recurrence rates.

    Quest also works with biotechnology companies that are developing next-generation molecular imaging dyes. These innovative dyes may enable Quest’s technology to advance diagnostic opportunities in fluorescence-guided cancer surgery.

    *Source: Transparency Market Research; Near-Infrared Fluorescence Imaging System Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2019-2027.

    About Quest

    Quest Photonic Devices B.V. is a multispectral imaging leader and focuses on the medical markets of fluorescence image-guided surgery and cancer-targeted probes. Quest’s next generation Spectrum Florescence Imaging System has the ability to “see through tissue” with enhanced sensitivity, capable of accessing otherwise inaccessible information to aid the surgeon in improving clinical outcomes.

    About Olympus’ Medical business

    As a leading medical technology company, Olympus’ Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients and their safety. Olympus’ Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com.

    For questions or additional information, please contact:

    Europe, Middle East and Africa
    Matthias Gengenbach
    +49 15142369420
    matthias.gengenbach@olympus-europa.com

    Japan and Asia Pacific
    Yuka Horimoto
    +81-90-2490-1071
    yuka_horimoto@ot.olympus.co.jp

    For the latest business and finance news in Asia - Business News Asia
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025

    June 9, 2025

    Traditional Chinese Medicine Consumption Shows Promising Outlook, with Neautus’s Market Leadership Becoming Increasingly Evident

    June 3, 2025

    First patient dosed in YK012 trial-the world’s first TCE therapy for primary membranous nephropathy

    May 29, 2025
    Latest News

    10 winners selected at 8th edition of Start-up Express

    June 12, 2025

    This Technology is Conquering the World: Neutrinovoltaics Redefining Global Infrastructure

    June 11, 2025

    HKTDC Design Gallery x STICKYLINE present: “Love HK” Exhibition

    June 11, 2025

    Blockpass partners with CryptoSwift to deliver global Travel Rule Compliance

    June 11, 2025

    U.S. Polo Assn. Returns as Official Apparel and Jersey Partner for Chestertons Polo in the Park in Downtown London

    June 10, 2025

    UK MOD Signs Protector Support Contract with GA-ASI

    June 10, 2025

    New HKTDC Chairman Frederick Ma keen to promote Hong Kong as best partner for global enterprises

    June 9, 2025

    SRKay Consulting Group Releases Research Report: ‘From Legal Frameworks to Successful Operations’–A Strategic Playbook for India Market Entry

    June 9, 2025

    Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025

    June 9, 2025

    Latest Firewall Vulnerability Reinforces Need for Post-Breach Privileged Access Controls – TACACS.net Offers a Critical Layer

    June 6, 2025

    TANAKA PRECIOUS METAL TECHNOLOGIES Receives 2025 Technology Award from Catalyst Manufacturers Association, Japan, for Development and Practical Application of Electrode Catalysts for PEM Water Electrolysis

    June 6, 2025

    Naoris Protocol Expands into the Nordics with Strategic Consulting Hub in Oslo

    June 5, 2025

    TF International Facilitates Hong Kong’s Successful Issuance of First Central Asian Sovereign Bond

    June 5, 2025

    LIMA’25 Wraps up with RM11 Billion in Deals and Record Global Participation

    June 4, 2025

    Global Communities Unite at centralwOrld as Thailand Steps Forward on Global LGBTQ+ Stage with Central Pattana’s Pride For All

    June 4, 2025
    BusinessNews.ph
    • Home
    • Business News Asia
    • Cebu Lifestyle Channel
    • Property News
    • Events News Asia.com
    • Contact Us
    • Cebu Business News
    © 2025 All Rights Reserved | BusinessNews.ph

    Type above and press Enter to search. Press Esc to cancel.